Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб., д. 7/9; 2ФГБУН «Институт эволюционной физиологии и биохимии им. И.М.Сеченова» РАН. 194223, Россия, Санкт-Петербург, пр. Тореза, д. 44 petrova_nn@mail.ru
Список исп. литературыСкрыть список 1. Ochoa S, Usall J, Cobo J et al. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. Schizophrenia Res Treatment 2012. DOI: 10.1155/2012/916198 2. Zhang XY, Chen DC, Xiu MH et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry 2012; 73: 1025–33. 3. Bergemann N, Parzer P, Runnebaum B et al. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007; 37 (10): 1427–36. 4. Crawford M, DeLisi L. Sex differences in pharmacologic treatments. Curr Opin Psychiatry 2016; 29 (3): 211–7. 5. Usall J, Suarez D, Haro JM, SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 2007; 153: 225–31. 6. Lieberman JA, Safferman AZ, Pollack S et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151 (12): 1744–52. 7. Szymanski S, Lieberman J, Pollack S et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry 1996; 39 (4): 249–54. 8. Tang YL, Mao P, Li F-M et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007; 64 (1): 49–56. 9. Kahn RS, Fleischhacker WW, Boter H et al, EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371 (9618): 1085–97. DOI: 10.1016/S0140-6736(08)60486-9 10. Ceskova E, Prikryl R, Libiger J et al. Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial. Schizophrenia Res 2015; 169: 303–7. 11. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int. Rev. Psychiatry 2010; 22: 417–28. 12. Cotton SM, Lambert M, Schimmelmann BG et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009; 114: 17–24. 13. Segarra R, Ojeda N, Zabala A et al. Similarities in early course among men and women with a first episode of schizophrenia and schizophreniformdisorder. Eur Arch Psychiatry Clin Neurosci 2012; 262 (2): 95–105. 14. Howard CH, Fiedosewicz H, Patel C et al. Treatment response and gender in patients with schizophrenia and schizoaffective disorder. Schizophrenia Res 2001; 49: 232. 15. Zhang J, Lou Y, Hoogmartens J, Van Schepdael A. Screening of drug metabolism by CE. Electrophoresis 2006; 27: 4827–35. 16. Bergiannaki JD, Kostaras P. Pharmacokinetic and pharmacodynamic effects of psychotropic medications: Differences between sexes. Psychiatriki 2016; 27 (2): 118–26. 17. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161 (8): 1324–33. 18. Seeman M. Women and psychosis. Womens Health 2012; 8: 215–24. 19. Lev-Ran S, Le Strat Y, Imtiaz S et al. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict 2013; 22 (1): 7–13. 20. Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology 2010; 35 (7): 1570–82. 21. Chavez C, Hollaus M, Scarr E et al. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010; 1321: 51–9. 22. Donner N, Handa RJ. Estrogen receptor beta regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neurosci 2009; 163 (2): 705–18. 23. Aichhorn W, Gasser M, Weiss EM et al. Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr Neuropharmacol 2005; 3: 73–85. 24. Goldstein JM, Cohen LS, Horton NJ et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 2002; 110 (1): 27–37. 25. Bigos KL, Pollock BG, Coley KC et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48 (2): 157–65. 26. Jablensky A, McGrath J, Herrman H et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000; 34 (2): 221–36. 27. Чумаков Е.М., Петрова Н.Н., Яковлев А.А., Смирнова И.О. Психические расстройства и социальная адаптация мужчин, больных сифилисом и ВИЧ-инфекцией. Соц. и клин. психиатрия. 2016; 26 (2): 10–3. / Chumakov E.M., Petrova N.N., Yakovlev A.A., Smirnova I.O. Psihicheskie rasstrojstva i socialnaya adaptaciya muzhchin, bolnyh sifilisom i VICh-infekciej. Soc. i klin. psihiatriya. 2016; 26 (2): 10–3. [in Russian] 28. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988; 22: 141–55. 29. Heitmiller DR, Nopoulos PC, Andreasen NC. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr Res 2004; 66: 137–42. 30. Parellada E, Lomena F, Catafau AM et al. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psych Res 2004; 130: 79–84. 31. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand (Suppl.) 2000; 401: 3–38. 32. Seeman M. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009; 35: 937–48. 33. Seeman M. Antipsychotics and physical attractiveness. Clin Schizophr Relat Psychoses 2011; 5: 142–6. 34. Lipkovich I, Citrome L, Perlis R et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006; 26 (3): 316–20. 35. Lipkovich I, Jacobson JG, Caldwell C et al. Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull 2009; 42 (4): 23–39. 36. Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Res 2005; 80: 45–53. 37. Enger C, Weatherby L, Reynolds RF et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nervous Mental Dis 2004; 192: 19–27. 38. Smith S, O’Keane V, Murray RM. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181: 49–55. 39. Perez-Iglesias R, Ortiz-Garcia de la Foz V, Martınez Garcıa O et al. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 2014; 159: 90–4. 40. Cuijpers P, Weitz E, Twisk J et al. Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. Depress Anxiety 2014; 31 (11): 941–51. 41. Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (1): 57–65. 42. Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157 (9): 1445–52. 43. Martenyi F, Dossenbach M, Mraz K et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001; 11 (3): 227–32. 44. Baca E, Garcia-Garcia M, Porras-Thase ME et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005; 14 (7): 609–16. 45. Deligiannidis KM, Rothschild AJ, Barton BA et al. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. J Clin Psychiatry 2013; 74 (10): 1003–9. 46. Huerta-Ramos E, Iniesta R, Ochoa S et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24 (2): 223–31. DOI: 10.1016/j.euroneuro.2013.11.012 47. Kulkarni J, Gavrilidis E, Wang W et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2015; 20 (6): 695–702. DOI: 10.1038/mp.2014.33 48. Weickert TW, Weinberg D et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 2015; 20 (6): 685–94. 49. Lange B, Mueller JK, Leweke FM, Bumb JM. How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. Expert Opin Pharmacother 2017; 18 (4): 351–62. DOI: 10.1080/14656566.2017.1288722 50. Parkinson A, Mudra DR, Johnson C et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193–209.